Replies to post #370 on Oscient Pharmaceuticals Corp (fka OSCIQ)

[All Teeth]

As I understand it,

1. For $5M, OSCIQ sold commercial right of Factive to Cornerstone Therapeutics which allows Cornerstone Therapeutics to produce Factive and compete with OSCIQ in the market OSCIQ already dominate.

2. OSCIQ reduced its sales force probably because they don't have a new drug out in the market. If OSCIQ is able to maintain their present customer accounts, they will mostly like maintain their revenue income.

3. With Salary Overhead reduced by a significant amount, OSCIQ's bottom line will be looking so good. A prime time for BUYOUT. I wouldn't advice the Mgmt to SELLOUT though.